Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 6:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,889 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
Questionaires, fMRI scan (optional)
Behavioral · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Cypionate, Sipuleucel-T
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Prostate Cancer
Interventions
bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
234
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more
Conditions
Recurrent Prostate Cancer After Surgery
Interventions
Daily-adaptive Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, New York
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide 7.5 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more
Conditions
Prostate Cancer
Interventions
Relugolix
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
96
States / cities
Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Hypofractionated Radiotherapy for Prostate Cancer

NCT00214097
Conditions
Prostate Cancer
Interventions
Radiotherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Conditions
Bony Metastases From Castrate Refractory Prostate Cancer
Interventions
Radium-223 dichloride
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer
Interventions
Brachytherapy
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
monoclonal antibody muJ591, iodine I 131 monoclonal antibody muJ591
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer Invasive, Prostate Cancer
Interventions
Audiovisual Intervention- Radiation Therapy Education, ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure, Audiovisual Intervention- Cancer Clinical Trials Education, NCI Taking Part in Cancer Research Studies Brochure
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Miami Beach, Florida • New York, New York
Conditions
Prostate Cancer
Interventions
Satraplatin plus radiation therapy
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
San Francisco, California • Dallas, Texas • San Antonio, Texas + 1 more
Conditions
Recurrent Prostate Cancer
Interventions
Verteporfin, SpectraCure P18 System
Drug · Device
Lead sponsor
SpectraCure AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer
Interventions
sargramostim, thalidomide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 120 Years · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-BBN, 67Cu-SAR-BBN
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Grand Rapids, Michigan + 3 more
Conditions
Prostate Cancer
Interventions
external beam radiation therapy, brachytherapy, questionnaires
Radiation · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Conditions
Prostate Cancer, Advanced Prostate Carcinoma
Interventions
Participant Surveys, Mobile app
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Prostatic Cancer
Interventions
High Dose Brachytherapy, Stereostatic Body Radiation Therapy
Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Prostate Cancer
Interventions
PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122
Drug
Lead sponsor
Ratio Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more
Conditions
Prostate Cancer
Interventions
surgery, radiation
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 75 Years · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
30
States / cities
Little Rock, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 26 more
Conditions
Prostate Cancer, Oligometastatic Disease
Interventions
niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia